Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Toxic as FK - A Case of Paxlovid-Induced Tacrolimus (FK506) Toxicity in a Kidney Transplant Recipient with COVID-19

Leitch-Casey et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/ajrccm.2025.211.Abstracts.A1193, May 2025
https://c19early.org/leitchcasey.html
Case report of a 71-year-old kidney transplant recipient who developed fatal tacrolimus toxicity after being prescribed paxlovid for COVID-19.
Leitch-Casey et al., 31 May 2025, peer-reviewed, 5 authors. Contact: lleitch3@hfhs.org.
Building, Level 2), Moscone Center
L Leitch-Casey, N Behbahani-Nejad, H Gidda, T Ng, R Franco-Elizondo
Introduction: The COVID-19 pandemic has posed significant challenges to solid organ transplantation, complicating the management of transplant recipients. Patients on immunosuppressive therapy are especially vulnerable to COVID-19 which, if not addressed promptly, can increase morbidity and mortality. The introduction of oral antiviral treatments, such as nirmatrelvir-ritonavir (Paxlovid), has improved access to COVID-19 therapies. However, these agents also increase the risk of drug interactions, which may amplify the toxicities of immunosuppressive medications, particularly calcineurin inhibitors (CNI) like tacrolimus (FK506). Case Report: A 71-year-old woman with a history of kidney transplantation, on low-dose prednisone, tacrolimus, and mycophenolic acid, presented with fever and severe fatigue for two days. Several family members had similar symptoms. After consulting her nephrologist, she was prescribed renally-adjusted Paxlovid for suspected COVID-19, with no changes to her immunosuppressive medications. Four days later, she returned with worsening symptoms, including shortness of breath, chills, and diffuse abdominal pain. She was diagnosed with sepsis secondary to COVID-19 and treated with intravenous fluids, broad-spectrum antibiotics, and remdesivir. Mycophenolic acid was discontinued, but tacrolimus was continued at the same dose. On the second day of hospitalization, laboratory results showed leukocytosis, metabolic acidosis, and significant electrolyte disturbances, including hypophosphatemia and hypomagnesemia. She also developed diarrhea and tremors, raising concern for tacrolimus toxicity. Shortly thereafter, the patient suffered a cardiac arrest. A tacrolimus level greater than 60 ng/mL resulted later that day, supporting the diagnosis. Following transfer to the medical intensive care unit, the patient developed seizure-like activity, raising concern for post-anoxic myoclonus or tacrolimus-induced seizures. Given that tacrolimus is not dialyzable, the critical care pharmacist and transplant nephrology team recommended initiating rifampin and phenytoin to enhance tacrolimus metabolism. Although these interventions successfully lowered tacrolimus levels, the patient remained comatose with MRI imaging revealing hypoxic-ischemic encephalopathy. After 14 days without neurological improvement, the family decided to pursue comfort care, and the patient ultimately passed away. Discussion: This case emphasizes the importance of caution when prescribing Paxlovid and other CYP3A4-inhibiting drugs to transplant recipients on immunosuppressive therapy. The interaction between ritonavir, a potent CYP3A4 inhibitor, and tacrolimus highlights the need for comprehensive, multidisciplinary management, including close collaboration with transplant specialists and pharmacists. Frequent monitoring of tacrolimus levels and timely recognition of toxicity are crucial to mitigate risks in this vulnerable population. Given the increasing use of CYP3A4..
DOI record: { "DOI": "10.1164/ajrccm.2025.211.abstracts.a1193", "ISSN": [ "1073-449X", "1535-4970" ], "URL": "http://dx.doi.org/10.1164/ajrccm.2025.211.Abstracts.A1193", "alternative-id": [ "10.1164/ajrccm.2025.211.Abstracts.A1193" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 3, "value": "2025-05-01" } ], "author": [ { "affiliation": [ { "name": "Internal Medicine, Henry Ford St. John Hospital, Detroit, MI, United States" } ], "family": "Leitch-Casey", "given": "L.", "sequence": "first" }, { "affiliation": [ { "name": "Internal Medicine, Henry Ford St. John Hospital, Detroit, MI, United States" } ], "family": "Behbahani-Nejad", "given": "N.", "sequence": "additional" }, { "affiliation": [ { "name": "Pulmonary, Critical Care and Sleep Medicine, Henry Ford St. John Hospital, Detroit, MI, United States" } ], "family": "Gidda", "given": "H.", "sequence": "additional" }, { "affiliation": [ { "name": "Pharmacy, Henry Ford St. John Hospital, Detroit, MI, United States" } ], "family": "Ng", "given": "T.H.", "sequence": "additional" }, { "affiliation": [ { "name": "Pulmonary, Critical Care and Sleep Medicine, Henry Ford St. John Hospital, Detroit, MI, United States" } ], "family": "Franco-Elizondo", "given": "R.", "sequence": "additional" } ], "container-title": "American Journal of Respiratory and Critical Care Medicine", "container-title-short": "Am J Respir Crit Care Med", "content-domain": { "crossmark-restriction": true, "domain": [ "www.atsjournals.org" ] }, "created": { "date-parts": [ [ 2025, 5, 11 ] ], "date-time": "2025-05-11T12:26:17Z", "timestamp": 1746966377000 }, "deposited": { "date-parts": [ [ 2025, 5, 11 ] ], "date-time": "2025-05-11T13:19:09Z", "timestamp": 1746969549000 }, "indexed": { "date-parts": [ [ 2025, 5, 11 ] ], "date-time": "2025-05-11T13:40:06Z", "timestamp": 1746970806811, "version": "3.40.5" }, "is-referenced-by-count": 0, "issue": "Abstracts", "issued": { "date-parts": [ [ 2025, 5 ] ] }, "journal-issue": { "issue": "Abstracts", "published-print": { "date-parts": [ [ 2025, 5 ] ] } }, "language": "en", "link": [ { "URL": "https://www.atsjournals.org/doi/pdf/10.1164/ajrccm.2025.211.Abstracts.A1193", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "19", "original-title": [], "page": "A1193-A1193", "prefix": "10.1164", "published": { "date-parts": [ [ 2025, 5 ] ] }, "published-print": { "date-parts": [ [ 2025, 5 ] ] }, "publisher": "American Thoracic Society", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://www.atsjournals.org/doi/10.1164/ajrccm.2025.211.Abstracts.A1193" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Toxic as FK - A Case of Paxlovid-Induced Tacrolimus (FK506) Toxicity in a Kidney Transplant Recipient with COVID-19", "type": "journal-article", "update-policy": "https://doi.org/10.1164/crossmarkpolicies", "volume": "211" }
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit